{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:25:47Z","timestamp":1777364747295,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.thromres.2016.04.020","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T21:15:03Z","timestamp":1461964503000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Improved antithrombotic activity and diminished bleeding side effect of a PEGylated \u03b1IIb\u03b23 antagonist, disintegrin"],"prefix":"10.1016","volume":"143","author":[{"given":"Chun-Chieh","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woei-Jer","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hu","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hsin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Chin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tur-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2016.04.020_bb0005","doi-asserted-by":"crossref","first-page":"21785","DOI":"10.1074\/jbc.R000003200","article-title":"Ligand binding to integrins","volume":"275","author":"Plow","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2016.04.020_bb0010","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3181\/00379727-195-43129B","article-title":"Disintegrins: a family of integrin inhibitory proteins from viper venoms","volume":"195","author":"Gould","year":"1990","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.thromres.2016.04.020_bb0015","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1160\/TH11-10-0727","article-title":"GPIIb\/IIIa inhibitors: from bench to bedside and back to bench again","volume":"107","author":"Armstrong","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.04.020_bb0020","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/CIRCRESAHA.112.300570","article-title":"Integrin \u03b1IIb\u03b23: from discovery to efficacious therapeutic target","volume":"112","author":"Bledzka","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.thromres.2016.04.020_bb0025","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrc2353","article-title":"Integrins in angiogenesis and lymphangiogenesis","volume":"8","author":"Avraamides","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.thromres.2016.04.020_bb0030","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0006-291X(91)91230-A","article-title":"A common precursor for a putative hemorrhagic protein and rhodostomin, a platelet aggregation inhibitor of the venom of Calloselasma rhodostoma: molecular cloning and sequence analysis","volume":"181","author":"Au","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.thromres.2016.04.020_bb0035","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1124\/mol.59.5.1333","article-title":"Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor by a selective alphaVbeta3 blockade of endothelial cells","volume":"59","author":"Yeh","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.thromres.2016.04.020_bb0040","first-page":"H1038","article-title":"Inhibition of platelet hemostatic plug formation by trigramin, a novel RGD-peptide","volume":"256","author":"Cook","year":"1989","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.thromres.2016.04.020_bb0045","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.thromres.2016.04.020_bb0050","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.thromres.2016.04.020_bb0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/mabi.200400140","article-title":"PEG-grafted chitosan as an injectable thermoreversible hydrogel","volume":"5","author":"Bhattarai","year":"2005","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.thromres.2016.04.020_bb0060","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/prot.1061","article-title":"Expression in Pichia patoris and characterization by circular dichroism and NMR of rhodostomin","volume":"43","author":"Guo","year":"2001","journal-title":"Proteins"},{"key":"10.1016\/j.thromres.2016.04.020_bb0065","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0169-409X(02)00022-4","article-title":"Chemistry for peptide and protein PEGylation","volume":"54","author":"Roberts","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.thromres.2016.04.020_bb0070","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2016.04.020_bb0075","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1021\/bc200187k","article-title":"PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects","volume":"22","author":"Kim","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.thromres.2016.04.020_bb0080","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/anie.200502113","article-title":"Polymer therapeutics: concepts and applications","volume":"45","author":"Haag","year":"2006","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.thromres.2016.04.020_bb0085","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.biocel.2005.01.014","article-title":"Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential","volume":"37","author":"Youn","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.thromres.2016.04.020_bb0090","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","article-title":"Pegylation: a novel process for modifying pharmacokinetics","volume":"40","author":"Harris","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.thromres.2016.04.020_bb0095","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1016\/S0021-9258(18)47710-1","article-title":"Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex","volume":"262","author":"Huang","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2016.04.020_bb0100","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/0006-2952(91)90256-5","article-title":"Halysin, an antiplatelet Arg\u2013Gly\u2013Asp-containing snake venom peptide, as fibrinogen receptor antagonist","volume":"42","author":"Huang","year":"1991","journal-title":"Biochem. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2016.04.020_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2005.01156.x","article-title":"Tailoring haemostatic treatment to patient requirements \u2014 an update on monitoring haemostatic response using thromboelastography","volume":"11","author":"Sorensen","year":"2005","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2016.04.020_bb0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0049-3848(93)90199-X","article-title":"Mouse antithrombotic assay. Inhibition of platelet thromboembolism by disintegrins","volume":"71","author":"Beviglia","year":"1993","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2016.04.020_bb0115","doi-asserted-by":"crossref","first-page":"e81165","DOI":"10.1371\/journal.pone.0081165","article-title":"Thrombolytic effects of the snake venom disintegrin saxatilin determined by novel assessment methods: a FeCl3-induced thrombosis model in mice","volume":"8","author":"Kwon","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2016.04.020_bb0120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jps.2600830432","article-title":"Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice","volume":"83","author":"Yamaoka","year":"1994","journal-title":"Pharm. Sci."},{"key":"10.1016\/j.thromres.2016.04.020_bb0125","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1021\/bi101926u","article-title":"How PEGylation enhances the stability and potency of insulin: a molecular dynamics simulation","volume":"50","author":"Yang","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.thromres.2016.04.020_bb0130","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1016\/S0021-9258(17)40291-2","article-title":"Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2016.04.020_bb0135","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.thromres.2016.04.020_bb0140","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.thromres.2016.04.020_bb0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2016.04.020_bb0150","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMc052880","article-title":"Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C","volume":"354","author":"van der Eijk","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2016.04.020_bb0155","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1538-7836.2010.04163.x","article-title":"Improvement of endotoxemic syndromes by a disintegrin, rhodostomin, through integrin alphaVbeta3 dependent pathway","volume":"9","author":"Hsu","year":"2011","journal-title":"J. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384816303188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384816303188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T09:06:44Z","timestamp":1655629604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384816303188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":31,"alternative-id":["S0049384816303188"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2016.04.020","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved antithrombotic activity and diminished bleeding side effect of a PEGylated \u03b1IIb\u03b23 antagonist, disintegrin","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2016.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}